

**SUMMARY OF STUDENT EVALUATIONS  
AY 2020/2021, Class of 2023**

Prepared by:

Andrea Braundmeier-Fleming, Ph.D.  
Associate Professor, Department of Medical Microbiology, Immunology and Cell Biology,  
Department of Obstetrics and Gynecology  
Year Two Curriculum Director, Office of Education and Curriculum

10/15/21

### EXECUTIVE SUMMARY

- SIU SOM's second year (Y2) of medical school is comprised of four units: Hematology/Immunology/Infectious Disease (HII), Cardio/Respiratory/Renal (CRR), Neural/Muscular/Behavioral (NMB), and Endocrine/Reproduction/Gastro (ERG).
- There were 74 total students in the Y2 cohort in AY 2020/2021
- Y2 students were asked to evaluate each unit as a whole. These are big picture data points.

Unit	Response Rate (out of 74 students)	Quality Rating (out of 5.0)	Time Devoted to Learning Activities (out of 5.0)
HII	38%	4.14	3.46
CRR	44%	3.79	3.81
NMB	30%	3.95	4.14
ERG	27%	3.55	3.60

- Things we learned:
  - Overall our response rate from the students is very low. Less than half of the class submitted a response. We do not require students to evaluate the units so this likely contributed to the low response rate. Also evaluations are completed immediately following sitting for the unit exam which may contribute to the low response rate.
  - Overall the quality rating of units is favorable but declines as the curricular year approaches Step 1 dedication time.
  - Students feel on average about the amount of time they are given to complete unit activities.
  - To gain a better understanding of how students evaluate our curriculum we MUST achieve a better response rate from our student population.

**SUMMARY of STUDENT EVALUATIONS BY Y2 UNIT  
(Bigger Picture)**

	Responses Rate (out of 76)	Quality Rating (out of 5)
<b>Hematology/Immunology/Infectious Disease (First Unit of Calendar Year Mid Aug-Mid Oct)</b>		
In general, this unit was successful in meeting its goals.	38%	4.14
The unit schedule had an appropriate amount of time devoted to learning activities (self-directed learning/studying, resource sessions, clinical experiences, doctoring mentor clinics, CAM, doctoring sessions).	38%	3.46
The Unit Directors were accessible and available.	38%	4.54
Doctoring Director (Y2)/Unit Nurse Educator (Y2) was accessible and available.	38%	4.64
Clinical skills session educators/observers (Y2)/assigned nurse educator (Y2) was a good resource for learning.	38%	4.64
The End-of-Unit Assessment provided a fair assessment of the knowledge, clinical skills, and professional attitudes/behaviors I developed during the unit.	38%	4.29
<b>Average</b>	<b>38%</b>	<b>4.28</b>

<b>Cardio/Respiratory/Renal (CRR) (Second Unit of Calendar Year Mid Oct-Dec)</b>		
In general, this unit was successful in meeting its goals.	44%	3.79
The unit schedule had an appropriate amount of time devoted to learning activities (self-directed learning/studying, resource sessions, clinical experiences, doctoring mentor clinics, CAM, doctoring sessions).	44%	3.81
The Unit Directors were accessible and available.	44%	3.68
Doctoring Director (Y2)/Unit Nurse Educator (Y2) was accessible and available.	44%	4.58
Clinical skills session educators/observers (Y2)/assigned nurse educator (Y2) was a good resource for learning.	44%	4.61
The End-of-Unit Assessment provided a fair assessment of the knowledge, clinical skills, and professional attitudes/behaviors I developed during the unit.	44%	3.90
<b>Average</b>	<b>44%</b>	<b>4.06</b>

<b>Neuro/Muscular/Behavioral (Third Unit of Calendar Year January-Mid March)</b>		
In general, this unit was successful in meeting its goals.	30%	3.95
The unit schedule had an appropriate amount of time devoted to learning activities (self-directed learning/studying, resource sessions, clinical experiences, doctoring mentor clinics, CAM, doctoring sessions).	30%	4.14
The Unit Directors were accessible and available.	30%	3.91
Doctoring Director (Y2)/Unit Nurse Educator (Y2) was accessible and available.	30%	4.41
Clinical skills session educators/observers (Y2)/assigned nurse educator (Y2) was a good resource for learning.	30%	4.50
The End-of-Unit Assessment provided a fair assessment of the knowledge, clinical skills, and professional attitudes/behaviors I developed during the unit.	30%	3.45
<b>Average</b>	<b>30%</b>	<b>4.06</b>

<b>Endocrine/Reproduction/Gastro (Fourth Unit of Calendar Year Mid March-May)</b>		
In general, this unit was successful in meeting its goals.	27%	3.55
The unit schedule had an appropriate amount of time devoted to learning activities (self-directed learning/studying, resource sessions, clinical experiences, doctoring mentor clinics, CAM, doctoring sessions).	27%	3.60
The Unit Directors were accessible and available.	27%	4.05
Doctoring Director (Y2)/Unit Nurse Educator (Y2) was accessible and available.	27%	4.50
Clinical skills session educators/observers (Y2)/assigned nurse educator (Y2) was a good resource for learning.	27%	4.50
The End-of-Unit Assessment provided a fair assessment of the knowledge, clinical skills, and professional attitudes/behaviors I developed during the unit.	27%	2.53
<b>Average</b>	<b>27%</b>	<b>3.79</b>

**SUMMARY OF STUDENT EVALUATIONS BY REQUIRED Y2 LEARNING EXPERIENCE BY UNIT**  
(Smaller Picture)

**Unit 1: Hematology/Immunology/Infectious Disease**

<b>Topic</b>	<b>Reporting</b>	<b>Score</b>
Bacterial Structure and Morphology	18	3.94
Innate Immunity to Bacterial Infections	20	4.37
Bacterial Virulence Factors	17	4
Staphylococcus	15	4.14
Microbial Genetics	16	4.07
Acquired Immunity	20	4.42
Epidemiology of Infectious Diseases	14	4.23
Integrated Clinical Case Conference	7	4
Integrated Clinical Case Conference	7	4.14
Gram Enteric	18	3.88
Pharmacokinetics	18	4.06
PSP	11	4
PSP	9	3.89
Pharm	19	4.37
ICC	12	4.17
ICC	10	3.78
ICC	10	3.7
Intro to Virology	18	4.06
SSRNA viruses	18	3.83
Neg ssRNA and dsRNA viruses	17	3.88
Vaccines	15	3.73
DNA viruses	18	3.94
Integrated Clinical Case Conference	9	3.89
Integrated Clinical Case Conference	10	3.8
Integrated Clinical Case Conference	10	3.9
Complex Ethical and Advanced Directives	8	4.13
Vector borne and Zoonotic Diseases	14	3.77
Intro to Hematology	17	4.25
Anemia and Red Cell Disorders	20	4.16
Myelodysplastic Syndromes	20	4.11
Acute Leukemia	18	3.47
Non Hodgkin Lymphoma	21	3.3
Hodgkin Lymphoma	20	3.67
Myeloproliferative Disease	19	3.67
Coagulation and Platelet	17	3.94
Pharmacology	21	4.15
ICC: Hematological Disease	11	3.91

ICC: Hematological Disease	11	4.18
Chronic HIV	17	4.4
Microbial Immune Evasion and Persistence	18	4.12
Radiology	16	4.44
ICC: Persistent Infectious Disease	13	4
ICC: Persistent Infectious Disease	13	3.92
Pharm	19	4.53
Immunodeficiency	19	4.42
Effector Mechanisms of Immune Injury	19	4.42
Pharm	16	4.2
ICC: Immunodeficiency	6	4.33
ICC: Immunodeficiency	6	4
<b>Average</b>	<b>15</b>	<b>4.034286</b>

## Unit 2: Cardiology/Respiratory/Renal

Topic	Reporting	Score
PSP	12	3.36
PSP	11	3.45
PSP	13	3.38
PSP	13	3.54
Pathology	11	3.91
Pharm/Diuretics	17	4.24
Pharm/Diuretics	16	4
Acid/Base Pathology	12	3.92
Path-Kidney	17	4.29
Path-Urinary	16	4.25
Pharm/thrombolytics	14	4.29
PSP	12	3.75
PSP	11	3.55
PSP	10	3.7
Pathology	16	4.33
Anticoagulants	10	4
CAD	15	4.07
Pathology	17	4.44
Acid/Base Pathology	14	4
Antiarrhythmics	13	4
Antiarrhythmics	11	4.09
Pathology	14	4.43
Pharm	10	4.1

Peripheral Vascular Disease	13	4.15
Antihyperlipids	10	4.3
Antihyperlipids	8	4
Valvular Heart Disease	14	4.31
Valvular Heart Disease	8	4
Heart Failure	10	4
Heart Failure	6	4
Path: Heart Failure	13	4.38
Pathology	16	4.5
Pathology	15	4.46
Pathology	6	3.83
Clinical: Smoking Cessation	5	3.8
Clinical: Smoking Cessation	11	4
Clinical: Smoking Cessation	12	3.92
Pathology	15	4.6
Clinical	10	4.1
Clinical	11	4.27
Clinical Pulmonary	9	3.78
Pathology	10	4.5
Pathology	8	4.13
Pathology	12	4.58
Pharmacology	10	4.1
Clinical	14	2.86
Radiology	12	4
Transfusion	8	4.13
<b>Average</b>	<b>11.89583333</b>	<b>4.037292</b>

### Unit 3: Neuro/Muscle/Behavior

Topic	Reporting	Score
Intro to Neuropharm	12	4.27
Pathology	6	4.2
Pathology	8	4.13
Pharm	10	3.9
Bone and Soft Tissue Tumors	10	3.22
Pharm	12	4.55
Demyelinating Disease	7	4.5
Demyelinating Disease	11	4.3
Demyelinating Disease	11	4
Spasticity and Neuromuscular Blockers	11	4.6
Neuro	9	4.5
Neuro	10	4.56

Neuro	9	4.25
Pathology	9	4.5
CVA Neuro	10	4.56
Pathology	10	4.33
Pharm	8	4.14
Coma	9	4.38
Epilepsy	10	4.11
Epilepsy	9	4.5
PSP	5	4.25
PSP	5	3.75
Head Trauma	1	5
Pharm	9	4
CNS Infection	9	3.88
Path	8	4.57
Path	12	4.45
Opioids, Pain, Migraine	11	4.3
Opioids, Pain, Migraine	11	4
Pharm	10	3.89
Pharm	10	4.33
Pharm	8	3.57
Pharm	9	4.38
Path	8	4.57
Path/Pharm	10	4.22
Path/Pharm	9	4.13
Pharm	9	4.22
Pharm	8	4.29
Psychiatirc Disorders	6	4.4
PSP	5	3
PSP	5	3.25
Radiology	13	4.23
Path&Pharm	11	4.1
Substance abuse	6	4.5
Substance abuse	6	4.67
Pharm	8	4.57
Pharm	4	4.67
<b>Average</b>	<b>8.659574468</b>	<b>4.227447</b>

#### Unit 4: Endocrine/Reproduction/Gastrointestinal

Topic	Reporting	Score
PSP	10	3.7
PSP	10	3.7



Obesity	8	4.5
Hypo/Pit	8	4.5
Pancreas/Duodenum	7	3.86
Pancreas/Duodenum	7	4.29
Parathyroid	4	4
Thyroid	5	4.2
Adrenals	7	4.29
Adrenals	7	3.86
Clinical Review Upper GI	7	4.57
Upper GI Pathology	8	4.5
Upper GI Pharmacology	6	4.83
Helminths	7	3.57
IDB	8	4.13
Clinical Review Lower GI	5	4.8
Lower GI Pharm	9	4.78
Lower GI Pathology	8	4.75
Diseases of Exocrine Pancreas	7	4.86
Hepatobiliary	8	4.75
CC	7	4.14
CC Clinical	6	4.67
Repro Endo Pharm	8	4.75
STI	8	4.25
Uterine Development	10	4.4
Uterine Development	8	3.38
Infertility	11	4.36
Pap Smears	8	4.38
Pap Smears	8	4.63
Gyne Onc	9	3.38
PSP	1	5
PSP	1	5
PSP	1	5
Pathology of Breast	9	4.33
Pregnancy	11	4.5
Pregnancy	11	4.3
SERMS	12	4.13
Male Repro	11	4.5
Clinical Male Repro	11	4.4
<b>Average</b>	<b>7.6153846</b>	<b>4.357</b>